TP53 and non-small cell lung carcinoma: To extend the concepts outlined in this paper, further pre-clinical studies should be carried out to investigate the ceralasertib-RT response of NSCLC models with alternative genetic mutations, including ATM and TP53 mutations, which are commonly mutated in NSCLC.